Next Article in Journal
A Comparison between Several Response Surface Methodology Designs and a Neural Network Model to Optimise the Oxidation Conditions of a Lignocellulosic Blend
Next Article in Special Issue
LOMIX, a Mixture of Flaxseed Linusorbs, Exerts Anti-Inflammatory Effects through Src and Syk in the NF-κB Pathway
Previous Article in Journal
Green Synthesis of MnO Nanoparticles Using Abutilon indicum Leaf Extract for Biological, Photocatalytic, and Adsorption Activities
Previous Article in Special Issue
Sorbaria kirilowii Ethanol Extract Exerts Anti-Inflammatory Effects In Vitro and In Vivo by Targeting Src/Nuclear Factor (NF)-κB
 
 
Article
Peer-Review Record

Oral Administration of Liquiritigenin Confers Protection from Atopic Dermatitis through the Inhibition of T Cell Activation

Biomolecules 2020, 10(5), 786; https://doi.org/10.3390/biom10050786
by Hyun-Su Lee, Eun-Nam Kim and Gil-Saeng Jeong *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomolecules 2020, 10(5), 786; https://doi.org/10.3390/biom10050786
Submission received: 30 April 2020 / Revised: 15 May 2020 / Accepted: 16 May 2020 / Published: 19 May 2020

Round 1

Reviewer 1 Report

The manuscript “Oral administration of liquiritigenin confers protection from atopic dermatitis through the inhibition of T cell activation” told us an interesting story, but some question are as follows.

  1. Why did you choose the dosage in oral administration of liquiritigenin?
  2. In order to testify the TLRF/NF-KB is involved the signal pathway, why did not use TLR4-antibody to block the TLR4 expression?

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Comments,

The manuscript concerns the oral administration of liquiritigenin confers protection from atopic dermatitis through the inhibition of T cell activation. The authors were studied further biological studies for natural flavanone liquiritigenin, which was isolated in 2015 from glycyrrhiza uralensis and possess strong estrogenic properties. Present manuscript authors showed that the liquiritigenin has an anti-atopic effect via control of T cell activation, and exhibits therapeutic potential for T cell-mediated disorders blocks T cell activation without cytotoxicity. These results are impressive and overall the manuscript is written well. therefore the manuscript could be acceptable for Biomolecules.

The reference for Nf-kB inhibitions is missing, include below reference for Nf-kB inhibition 

  1. Mohapatra, D. K.; Reddy, D. S.; Ramaiah, M. J.; Ghosh, S.; Pothula, V.; Lunavath, S.; Thomas, S.; Valli. S. N.; Bhadra, M. P.; Yadav, J. S. Rugulactone derivatives act as inhibitors of NF-κB activation and modulates the transcription of NF-κB dependent genes in MDA-MB-231cells. Bioorg. Med. Chem. Lett Bioorg. Med. Chem. Lett. 2014, 24,1389-1396.
  2. Mohapatra, D. K.; Das, P. P.; Reddy, D. S.; Yadav, J. S. First total syntheses and absolute configuration of rugulactone and 6 (R)-(4′-oxopent-2′-enyl)-5, 6-dihydro-2H-pyran-2-one. Tetrahedron Lett. 2009, 50, 5941-5944

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop